ProCE Banner Activity

Phase II ZUMA-2 Trial of KTE-X19 CAR T-Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma

Slideset Download
Conference Coverage
KTE-X19, a CD19-directed CAR T-cell therapy, produced high and durable response rates in relapsed/refractory mantle cell lymphoma.

Released: December 15, 2019

Expiration: December 13, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company